Loading…
Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT2A receptor
The intricate involvement of the serotonin 5-HT 2A receptor (5-HT 2A R) both in schizophrenia and in the activity of antipsychotic drugs is widely acknowledged. The currently marketed antipsychotic drugs, although effective in managing the symptoms of schizophrenia to a certain extent, are not witho...
Saved in:
Published in: | Molecular psychiatry 2024-09, Vol.29 (9), p.2753-2764 |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c403t-d198b8775944ccdca59d04d8ade8cdf1fb38eab3ebbe956ae82ca10607eda39b3 |
container_end_page | 2764 |
container_issue | 9 |
container_start_page | 2753 |
container_title | Molecular psychiatry |
container_volume | 29 |
creator | Gaitonde, Supriya A. Avet, Charlotte de la Fuente Revenga, Mario Blondel-Tepaz, Elodie Shahraki, Aida Pastor, Adrian Morales Talagayev, Valerij Robledo, Patricia Kolb, Peter Selent, Jana González-Maeso, Javier Bouvier, Michel |
description | The intricate involvement of the serotonin 5-HT
2A
receptor (5-HT
2A
R) both in schizophrenia and in the activity of antipsychotic drugs is widely acknowledged. The currently marketed antipsychotic drugs, although effective in managing the symptoms of schizophrenia to a certain extent, are not without their repertoire of serious side effects. There is a need for better therapeutics to treat schizophrenia for which understanding the mechanism of action of the current antipsychotic drugs is imperative. With bioluminescence resonance energy transfer (BRET) assays, we trace the signaling signature of six antipsychotic drugs belonging to three generations at the 5-HT
2A
R for the entire spectrum of signaling pathways activated by serotonin (5-HT). The antipsychotic drugs display previously unidentified pathway preference at the level of the individual Gα subunits and β-arrestins. In particular, risperidone, clozapine, olanzapine and haloperidol showed G protein-selective inverse agonist activity. In addition, G protein-selective partial agonism was found for aripiprazole and cariprazine. Pathway-specific apparent dissociation constants determined from functional analyses revealed distinct coupling-modulating capacities of the tested antipsychotics at the different 5-HT-activated pathways. Computational analyses of the pharmacological and structural fingerprints support a mechanistically based clustering that recapitulate the clinical classification (typical/first generation, atypical/second generation, third generation) of the antipsychotic drugs. The study provides a new framework to functionally classify antipsychotics that should represent a useful tool for the identification of better and safer neuropsychiatric drugs and allows formulating hypotheses on the links between specific signaling cascades and in the clinical outcomes of the existing drugs. |
doi_str_mv | 10.1038/s41380-024-02531-7 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11420065</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3031132256</sourcerecordid><originalsourceid>FETCH-LOGICAL-c403t-d198b8775944ccdca59d04d8ade8cdf1fb38eab3ebbe956ae82ca10607eda39b3</originalsourceid><addsrcrecordid>eNp9UcFqGzEQFSWldt3-QE6CXHLZRlpJu9pTCCFpCoYUkp6FVpq1ZdaSK2kD-fvIsWloDjkMMzDvPd7MQ-iUkh-UMHmROGWSVKTmpQSjVfsJzSlvm0qIVp6UmYmu4lTyGfqa0oaQ_VJ8QTMmRUN5087Rw--1jlttwhhWzugRD86vIO6i8xmHAWuf3S49m3XIzmAbp1XCOuO8Bpwghhy881hUd4_1FY5gYJdD_IY-D3pM8P3YF-jP7c3j9V21vP_56_pqWRlOWK4s7WQv21Z0nBtjjRadJdxKbUEaO9ChZxJ0z6DvoRONBlkbTUlDWrCadT1boMuD7m7qt2AN-Bz1qIr3rY7PKmin_t94t1ar8KQo5TUhjSgK50eFGP5OkLLaumRgHLWHMCXFCKOU1bVoCvTsHXQTpujLfYpRIjnngsmCqg8oE0NKEYZ_bihR-9DUITRVQlOvoam2kNiBlPZvL99_k_6A9QKVoppx</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3108444538</pqid></control><display><type>article</type><title>Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT2A receptor</title><source>Springer Nature</source><source>Alma/SFX Local Collection</source><creator>Gaitonde, Supriya A. ; Avet, Charlotte ; de la Fuente Revenga, Mario ; Blondel-Tepaz, Elodie ; Shahraki, Aida ; Pastor, Adrian Morales ; Talagayev, Valerij ; Robledo, Patricia ; Kolb, Peter ; Selent, Jana ; González-Maeso, Javier ; Bouvier, Michel</creator><creatorcontrib>Gaitonde, Supriya A. ; Avet, Charlotte ; de la Fuente Revenga, Mario ; Blondel-Tepaz, Elodie ; Shahraki, Aida ; Pastor, Adrian Morales ; Talagayev, Valerij ; Robledo, Patricia ; Kolb, Peter ; Selent, Jana ; González-Maeso, Javier ; Bouvier, Michel</creatorcontrib><description>The intricate involvement of the serotonin 5-HT
2A
receptor (5-HT
2A
R) both in schizophrenia and in the activity of antipsychotic drugs is widely acknowledged. The currently marketed antipsychotic drugs, although effective in managing the symptoms of schizophrenia to a certain extent, are not without their repertoire of serious side effects. There is a need for better therapeutics to treat schizophrenia for which understanding the mechanism of action of the current antipsychotic drugs is imperative. With bioluminescence resonance energy transfer (BRET) assays, we trace the signaling signature of six antipsychotic drugs belonging to three generations at the 5-HT
2A
R for the entire spectrum of signaling pathways activated by serotonin (5-HT). The antipsychotic drugs display previously unidentified pathway preference at the level of the individual Gα subunits and β-arrestins. In particular, risperidone, clozapine, olanzapine and haloperidol showed G protein-selective inverse agonist activity. In addition, G protein-selective partial agonism was found for aripiprazole and cariprazine. Pathway-specific apparent dissociation constants determined from functional analyses revealed distinct coupling-modulating capacities of the tested antipsychotics at the different 5-HT-activated pathways. Computational analyses of the pharmacological and structural fingerprints support a mechanistically based clustering that recapitulate the clinical classification (typical/first generation, atypical/second generation, third generation) of the antipsychotic drugs. The study provides a new framework to functionally classify antipsychotics that should represent a useful tool for the identification of better and safer neuropsychiatric drugs and allows formulating hypotheses on the links between specific signaling cascades and in the clinical outcomes of the existing drugs.</description><identifier>ISSN: 1359-4184</identifier><identifier>ISSN: 1476-5578</identifier><identifier>EISSN: 1476-5578</identifier><identifier>DOI: 10.1038/s41380-024-02531-7</identifier><identifier>PMID: 38561467</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>13/109 ; 13/95 ; 14/33 ; 14/35 ; 14/5 ; 631/154 ; 631/1647 ; 692/699/476/1799 ; 82/80 ; 96/10 ; 96/106 ; Antipsychotics ; Aripiprazole ; Arrestin ; Behavioral Sciences ; Biological Psychology ; Bioluminescence ; Clozapine ; Drugs ; Haloperidol ; Inverse agonists ; Medicine ; Medicine & Public Health ; Mental disorders ; Neurosciences ; Olanzapine ; Pharmacotherapy ; Psychiatry ; Psychotropic drugs ; Risperidone ; Schizophrenia ; Serotonin ; Serotonin S2 receptors ; Signal transduction</subject><ispartof>Molecular psychiatry, 2024-09, Vol.29 (9), p.2753-2764</ispartof><rights>The Author(s) 2024</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c403t-d198b8775944ccdca59d04d8ade8cdf1fb38eab3ebbe956ae82ca10607eda39b3</cites><orcidid>0000-0003-3105-3204 ; 0000-0002-1907-9594 ; 0000-0002-7941-0939 ; 0000-0003-4089-614X ; 0000-0003-1128-0100</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids></links><search><creatorcontrib>Gaitonde, Supriya A.</creatorcontrib><creatorcontrib>Avet, Charlotte</creatorcontrib><creatorcontrib>de la Fuente Revenga, Mario</creatorcontrib><creatorcontrib>Blondel-Tepaz, Elodie</creatorcontrib><creatorcontrib>Shahraki, Aida</creatorcontrib><creatorcontrib>Pastor, Adrian Morales</creatorcontrib><creatorcontrib>Talagayev, Valerij</creatorcontrib><creatorcontrib>Robledo, Patricia</creatorcontrib><creatorcontrib>Kolb, Peter</creatorcontrib><creatorcontrib>Selent, Jana</creatorcontrib><creatorcontrib>González-Maeso, Javier</creatorcontrib><creatorcontrib>Bouvier, Michel</creatorcontrib><title>Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT2A receptor</title><title>Molecular psychiatry</title><addtitle>Mol Psychiatry</addtitle><description>The intricate involvement of the serotonin 5-HT
2A
receptor (5-HT
2A
R) both in schizophrenia and in the activity of antipsychotic drugs is widely acknowledged. The currently marketed antipsychotic drugs, although effective in managing the symptoms of schizophrenia to a certain extent, are not without their repertoire of serious side effects. There is a need for better therapeutics to treat schizophrenia for which understanding the mechanism of action of the current antipsychotic drugs is imperative. With bioluminescence resonance energy transfer (BRET) assays, we trace the signaling signature of six antipsychotic drugs belonging to three generations at the 5-HT
2A
R for the entire spectrum of signaling pathways activated by serotonin (5-HT). The antipsychotic drugs display previously unidentified pathway preference at the level of the individual Gα subunits and β-arrestins. In particular, risperidone, clozapine, olanzapine and haloperidol showed G protein-selective inverse agonist activity. In addition, G protein-selective partial agonism was found for aripiprazole and cariprazine. Pathway-specific apparent dissociation constants determined from functional analyses revealed distinct coupling-modulating capacities of the tested antipsychotics at the different 5-HT-activated pathways. Computational analyses of the pharmacological and structural fingerprints support a mechanistically based clustering that recapitulate the clinical classification (typical/first generation, atypical/second generation, third generation) of the antipsychotic drugs. The study provides a new framework to functionally classify antipsychotics that should represent a useful tool for the identification of better and safer neuropsychiatric drugs and allows formulating hypotheses on the links between specific signaling cascades and in the clinical outcomes of the existing drugs.</description><subject>13/109</subject><subject>13/95</subject><subject>14/33</subject><subject>14/35</subject><subject>14/5</subject><subject>631/154</subject><subject>631/1647</subject><subject>692/699/476/1799</subject><subject>82/80</subject><subject>96/10</subject><subject>96/106</subject><subject>Antipsychotics</subject><subject>Aripiprazole</subject><subject>Arrestin</subject><subject>Behavioral Sciences</subject><subject>Biological Psychology</subject><subject>Bioluminescence</subject><subject>Clozapine</subject><subject>Drugs</subject><subject>Haloperidol</subject><subject>Inverse agonists</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mental disorders</subject><subject>Neurosciences</subject><subject>Olanzapine</subject><subject>Pharmacotherapy</subject><subject>Psychiatry</subject><subject>Psychotropic drugs</subject><subject>Risperidone</subject><subject>Schizophrenia</subject><subject>Serotonin</subject><subject>Serotonin S2 receptors</subject><subject>Signal transduction</subject><issn>1359-4184</issn><issn>1476-5578</issn><issn>1476-5578</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9UcFqGzEQFSWldt3-QE6CXHLZRlpJu9pTCCFpCoYUkp6FVpq1ZdaSK2kD-fvIsWloDjkMMzDvPd7MQ-iUkh-UMHmROGWSVKTmpQSjVfsJzSlvm0qIVp6UmYmu4lTyGfqa0oaQ_VJ8QTMmRUN5087Rw--1jlttwhhWzugRD86vIO6i8xmHAWuf3S49m3XIzmAbp1XCOuO8Bpwghhy881hUd4_1FY5gYJdD_IY-D3pM8P3YF-jP7c3j9V21vP_56_pqWRlOWK4s7WQv21Z0nBtjjRadJdxKbUEaO9ChZxJ0z6DvoRONBlkbTUlDWrCadT1boMuD7m7qt2AN-Bz1qIr3rY7PKmin_t94t1ar8KQo5TUhjSgK50eFGP5OkLLaumRgHLWHMCXFCKOU1bVoCvTsHXQTpujLfYpRIjnngsmCqg8oE0NKEYZ_bihR-9DUITRVQlOvoam2kNiBlPZvL99_k_6A9QKVoppx</recordid><startdate>20240901</startdate><enddate>20240901</enddate><creator>Gaitonde, Supriya A.</creator><creator>Avet, Charlotte</creator><creator>de la Fuente Revenga, Mario</creator><creator>Blondel-Tepaz, Elodie</creator><creator>Shahraki, Aida</creator><creator>Pastor, Adrian Morales</creator><creator>Talagayev, Valerij</creator><creator>Robledo, Patricia</creator><creator>Kolb, Peter</creator><creator>Selent, Jana</creator><creator>González-Maeso, Javier</creator><creator>Bouvier, Michel</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3105-3204</orcidid><orcidid>https://orcid.org/0000-0002-1907-9594</orcidid><orcidid>https://orcid.org/0000-0002-7941-0939</orcidid><orcidid>https://orcid.org/0000-0003-4089-614X</orcidid><orcidid>https://orcid.org/0000-0003-1128-0100</orcidid></search><sort><creationdate>20240901</creationdate><title>Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT2A receptor</title><author>Gaitonde, Supriya A. ; Avet, Charlotte ; de la Fuente Revenga, Mario ; Blondel-Tepaz, Elodie ; Shahraki, Aida ; Pastor, Adrian Morales ; Talagayev, Valerij ; Robledo, Patricia ; Kolb, Peter ; Selent, Jana ; González-Maeso, Javier ; Bouvier, Michel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c403t-d198b8775944ccdca59d04d8ade8cdf1fb38eab3ebbe956ae82ca10607eda39b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>13/109</topic><topic>13/95</topic><topic>14/33</topic><topic>14/35</topic><topic>14/5</topic><topic>631/154</topic><topic>631/1647</topic><topic>692/699/476/1799</topic><topic>82/80</topic><topic>96/10</topic><topic>96/106</topic><topic>Antipsychotics</topic><topic>Aripiprazole</topic><topic>Arrestin</topic><topic>Behavioral Sciences</topic><topic>Biological Psychology</topic><topic>Bioluminescence</topic><topic>Clozapine</topic><topic>Drugs</topic><topic>Haloperidol</topic><topic>Inverse agonists</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mental disorders</topic><topic>Neurosciences</topic><topic>Olanzapine</topic><topic>Pharmacotherapy</topic><topic>Psychiatry</topic><topic>Psychotropic drugs</topic><topic>Risperidone</topic><topic>Schizophrenia</topic><topic>Serotonin</topic><topic>Serotonin S2 receptors</topic><topic>Signal transduction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gaitonde, Supriya A.</creatorcontrib><creatorcontrib>Avet, Charlotte</creatorcontrib><creatorcontrib>de la Fuente Revenga, Mario</creatorcontrib><creatorcontrib>Blondel-Tepaz, Elodie</creatorcontrib><creatorcontrib>Shahraki, Aida</creatorcontrib><creatorcontrib>Pastor, Adrian Morales</creatorcontrib><creatorcontrib>Talagayev, Valerij</creatorcontrib><creatorcontrib>Robledo, Patricia</creatorcontrib><creatorcontrib>Kolb, Peter</creatorcontrib><creatorcontrib>Selent, Jana</creatorcontrib><creatorcontrib>González-Maeso, Javier</creatorcontrib><creatorcontrib>Bouvier, Michel</creatorcontrib><collection>SpringerOpen</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gaitonde, Supriya A.</au><au>Avet, Charlotte</au><au>de la Fuente Revenga, Mario</au><au>Blondel-Tepaz, Elodie</au><au>Shahraki, Aida</au><au>Pastor, Adrian Morales</au><au>Talagayev, Valerij</au><au>Robledo, Patricia</au><au>Kolb, Peter</au><au>Selent, Jana</au><au>González-Maeso, Javier</au><au>Bouvier, Michel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT2A receptor</atitle><jtitle>Molecular psychiatry</jtitle><stitle>Mol Psychiatry</stitle><date>2024-09-01</date><risdate>2024</risdate><volume>29</volume><issue>9</issue><spage>2753</spage><epage>2764</epage><pages>2753-2764</pages><issn>1359-4184</issn><issn>1476-5578</issn><eissn>1476-5578</eissn><abstract>The intricate involvement of the serotonin 5-HT
2A
receptor (5-HT
2A
R) both in schizophrenia and in the activity of antipsychotic drugs is widely acknowledged. The currently marketed antipsychotic drugs, although effective in managing the symptoms of schizophrenia to a certain extent, are not without their repertoire of serious side effects. There is a need for better therapeutics to treat schizophrenia for which understanding the mechanism of action of the current antipsychotic drugs is imperative. With bioluminescence resonance energy transfer (BRET) assays, we trace the signaling signature of six antipsychotic drugs belonging to three generations at the 5-HT
2A
R for the entire spectrum of signaling pathways activated by serotonin (5-HT). The antipsychotic drugs display previously unidentified pathway preference at the level of the individual Gα subunits and β-arrestins. In particular, risperidone, clozapine, olanzapine and haloperidol showed G protein-selective inverse agonist activity. In addition, G protein-selective partial agonism was found for aripiprazole and cariprazine. Pathway-specific apparent dissociation constants determined from functional analyses revealed distinct coupling-modulating capacities of the tested antipsychotics at the different 5-HT-activated pathways. Computational analyses of the pharmacological and structural fingerprints support a mechanistically based clustering that recapitulate the clinical classification (typical/first generation, atypical/second generation, third generation) of the antipsychotic drugs. The study provides a new framework to functionally classify antipsychotics that should represent a useful tool for the identification of better and safer neuropsychiatric drugs and allows formulating hypotheses on the links between specific signaling cascades and in the clinical outcomes of the existing drugs.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>38561467</pmid><doi>10.1038/s41380-024-02531-7</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-3105-3204</orcidid><orcidid>https://orcid.org/0000-0002-1907-9594</orcidid><orcidid>https://orcid.org/0000-0002-7941-0939</orcidid><orcidid>https://orcid.org/0000-0003-4089-614X</orcidid><orcidid>https://orcid.org/0000-0003-1128-0100</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1359-4184 |
ispartof | Molecular psychiatry, 2024-09, Vol.29 (9), p.2753-2764 |
issn | 1359-4184 1476-5578 1476-5578 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11420065 |
source | Springer Nature; Alma/SFX Local Collection |
subjects | 13/109 13/95 14/33 14/35 14/5 631/154 631/1647 692/699/476/1799 82/80 96/10 96/106 Antipsychotics Aripiprazole Arrestin Behavioral Sciences Biological Psychology Bioluminescence Clozapine Drugs Haloperidol Inverse agonists Medicine Medicine & Public Health Mental disorders Neurosciences Olanzapine Pharmacotherapy Psychiatry Psychotropic drugs Risperidone Schizophrenia Serotonin Serotonin S2 receptors Signal transduction |
title | Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT2A receptor |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T19%3A29%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacological%20fingerprint%20of%20antipsychotic%20drugs%20at%20the%20serotonin%205-HT2A%20receptor&rft.jtitle=Molecular%20psychiatry&rft.au=Gaitonde,%20Supriya%20A.&rft.date=2024-09-01&rft.volume=29&rft.issue=9&rft.spage=2753&rft.epage=2764&rft.pages=2753-2764&rft.issn=1359-4184&rft.eissn=1476-5578&rft_id=info:doi/10.1038/s41380-024-02531-7&rft_dat=%3Cproquest_pubme%3E3031132256%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c403t-d198b8775944ccdca59d04d8ade8cdf1fb38eab3ebbe956ae82ca10607eda39b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3108444538&rft_id=info:pmid/38561467&rfr_iscdi=true |